Skip to content

Food and Drug Recall.org

The Latest Food & Drug Recall and Safety News

FDA authorizes use of first device to treat patients with dialysis-related amyloidosis

March 6, 2015Drug Recalls & Safety Notices, Drug Safety Information Podcasts, Food & Drug Recalls, Food Safety Newsadmin

The U.S. Food and Drug Administration today authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA).

Post navigation

← FDA approves first biosimilar product Zarxio Hospira Issues a Voluntary Nationwide Recall of One Lot of Magnesium Sulfate in 5% Dextrose Injection Due to Incorrect Barcode Labeling →
Proudly powered by WordPress